List of Excipients in Branded Drug DUAVEE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	DUAVEE	conjugated estrogens/bazedoxifene	0008-1123	ASCORBIC ACID	2027-03-10
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	DUAVEE	conjugated estrogens/bazedoxifene	0008-1123	CELLULOSE, MICROCRYSTALLINE	2027-03-10
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	DUAVEE	conjugated estrogens/bazedoxifene	0008-1123	FERRIC OXIDE RED	2027-03-10

# Duavee Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and IP Analysis

Last updated: August 6, 2026

Duavee is a fixed-dose oral tablet containing conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg. Its commercial value comes from combining estrogen therapy with a selective estrogen receptor modulator, allowing treatment of moderate-to-severe vasomotor symptoms while reducing the need for a progestin in women with a uterus. The principal excipient opportunities are not new therapeutic claims but improved manufacturability, dose uniformity, stability, patient acceptability, and differentiated generic or reformulated products.

What is Duavee and how is it regulated?

Duavee is marketed by Pfizer and was approved by the U.S. Food and Drug Administration on October 3, 2013, under NDA 022247. The active ingredients are conjugated estrogens and bazedoxifene acetate. The marketed strength contains 0.45 mg of conjugated estrogens and bazedoxifene acetate equivalent to 20 mg of bazedoxifene.[1]

The FDA-approved indications are:

• Treatment of moderate-to-severe vasomotor symptoms associated with menopause.
• Prevention of postmenopausal osteoporosis in women with a uterus.

Duavee is not approved for treatment of established osteoporosis. The product is taken once daily and is supplied as an oral, immediate-release, film-coated tablet.[1]

What are the active pharmaceutical ingredients?

Conjugated estrogens are a mixture of estrogenic compounds, including estrone sulfate and equilin sulfate derivatives. Bazedoxifene is a selective estrogen receptor modulator. The combination is intended to provide estrogenic benefits in target tissues while allowing bazedoxifene to oppose estrogen activity in the endometrium.

The formulation creates a difficult analytical and manufacturing profile because the estrogen component is present at a very low dose relative to bazedoxifene. Content uniformity, segregation control, blend homogeneity, and validated assay methods are central development issues.

What excipients are used in Duavee tablets?

The FDA prescribing information identifies the following inactive ingredients for Duavee tablets:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Diluent, dry binder, disintegration support
Hypromellose	Film-forming polymer and coating component
Magnesium stearate	Lubricant
Polydextrose	Tablet or coating excipient
Polyethylene glycol	Plasticizer or coating component
Sucrose	Coating or film-coating component
Titanium dioxide	Opacifier and whitening agent
Triacetin	Coating plasticizer

The exact qualitative and quantitative composition is proprietary. FDA labeling identifies inactive ingredients but does not disclose the complete manufacturing formula, grade, particle-size distribution, granulation parameters, coating weight, or supplier specifications.[1]

Which excipients are most important for Duavee performance?

Lactose monohydrate and microcrystalline cellulose are likely to control tablet weight, compactability, blend uniformity, and disintegration. Magnesium stearate requires careful optimization because excessive lubrication can reduce tablet tensile strength and slow dissolution.

The coating system is also commercially relevant. Hypromellose, polyethylene glycol, sucrose, titanium dioxide, and triacetin can be adjusted to improve:

• Moisture protection.
• Tablet appearance.
• Mechanical resistance.
• Swallowability.
• Film adhesion.
• Packaging stability.
• Manufacturing throughput.

Because conjugated estrogens are a mixture rather than a single chemically defined molecule, analytical control of the finished product is more complex than for a conventional single-API tablet. Excipient changes must therefore be assessed for their effect on assay, dissolution, impurity formation, and component-specific uniformity.

What excipient strategy is most attractive for Duavee?

The strongest commercial strategy is a platform that improves low-dose combination-tablet manufacturability without changing the product’s clinical profile.

1. Improve content uniformity

The 0.45 mg conjugated-estrogen dose creates a high dilution ratio against the 20 mg bazedoxifene dose and the excipient mass. Direct blending can create segregation risks based on differences in particle size, density, morphology, and electrostatic behavior.

Potential approaches include:

• Ordered mixing using engineered carrier particles.
• Co-processing of microcrystalline cellulose with a secondary filler.
• Roller compaction with controlled granule size.
• Wet granulation, if chemical and physical stability are maintained.
• API layering or dry coating of the low-dose estrogen fraction.
• Spray-dried intermediate powders.
• Particle-size matching between active ingredients and major diluents.

The most defensible technology would need to demonstrate improved blend uniformity without creating a new dissolution or stability problem.

2. Reduce lubricant sensitivity

Magnesium stearate can improve ejection but may produce hydrophobic over-lubrication. A differentiated formulation could use:

• Lower lubricant concentration.
• Shorter lubrication time.
• Alternative lubricant systems.
• Structured lubrication using external lubrication equipment.
• Co-processed excipients that reduce dependence on magnesium stearate.

A lower-lubricant process may improve dissolution and tablet strength, but it would need to preserve manufacturability at commercial compression speeds.

3. Improve moisture and stability control

Duavee contains a low-dose estrogen mixture and a SERM. Moisture exposure can affect powder flow, tablet strength, coating integrity, and chemical stability. Commercial opportunities include:

• Low-moisture excipient grades.
• Moisture-barrier film coatings.
• Desiccant-compatible packaging.
• High-barrier blister packs.
• Improved container-closure systems.
• Excipient selection that limits water activity.
• Process controls for coating-room humidity.

Packaging may provide a more practical lifecycle opportunity than a major change to the tablet core. A formulation that permits standard high-barrier blister packaging, reduced desiccant use, or longer in-use stability could create value for generic manufacturers and international markets.

4. Address lactose sensitivity and dietary restrictions

The current product contains lactose monohydrate. A lactose-free version could appeal to patients who avoid lactose or to markets where lactose-free labeling has commercial value. Substitutes could include mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose, or co-processed polyols.

A lactose-free formulation would require comparative evaluation of:

• Tablet hardness.
• Friability.
• Disintegration.
• Dissolution of both active components.
• Moisture uptake.
• Blend uniformity.
• Mouthfeel and swallowability.
• Bioequivalence.

The opportunity is commercially plausible but may have limited patient value unless lactose content is clinically meaningful and the alternative formulation preserves equivalent performance.

What formulations are protected by Duavee patents?

Duavee’s intellectual-property protection is likely to include multiple layers rather than a single formulation claim:

1. The combination of conjugated estrogens and bazedoxifene.
2. Specific dose ratios and dosage strengths.
3. Methods of treating menopausal vasomotor symptoms.
4. Methods of preventing postmenopausal bone loss.
5. Pharmaceutical compositions and oral dosage forms.
6. Manufacturing or formulation features, depending on the issued patent claims.
7. Regulatory exclusivity associated with the approved NDA.

The relevant patent family should be reviewed in the USPTO Patent Center, FDA Orange Book, and patent litigation databases. Patent scope can differ materially between U.S., European, Canadian, Japanese, and other national filings. A patent that covers the active combination may not block an excipient-only formulation if the generic does not practice the claimed limitation. Conversely, a formulation claim can create a narrower but commercially important barrier if it recites a specific excipient, ratio, dissolution profile, particle-size range, or manufacturing step.

How strong is the Duavee patent estate?

The estate is strongest where claims cover the fixed-dose combination or a required therapeutic method. It is weaker against a design-around that preserves the active ingredients but changes:

• Diluent system.
• Granulation process.
• Lubricant.
• Coating composition.
• Particle-size distribution.
• Packaging configuration.
• Noninfringing method-of-use labeling.

The commercial blocking power depends on the current Orange Book listings, patent expiration dates, pediatric extensions, terminal disclaimers, and the scope of any FDA-recognized method-of-use claims. Patent strength should therefore be assessed claim by claim rather than by patent count.

When does Duavee lose exclusivity?

Duavee’s FDA approval date was October 3, 2013. Any five-year new chemical entity exclusivity associated with the NDA would have expired in 2018, subject to the specific FDA exclusivity code assigned to the product. Three-year clinical-investigation exclusivity, if applicable to a particular approval basis, would have expired earlier.[1,2]

Patent protection can extend beyond regulatory exclusivity. The controlling date for generic entry is the latest enforceable patent that covers the product, its use, or a required formulation element, subject to litigation and settlement outcomes.

Protection layer	Relevance to Duavee
New chemical entity exclusivity	Statutory period tied to the 2013 approval
New clinical investigation exclusivity	May apply to qualifying approval activities
Orange Book patents	Can require Paragraph IV certification by an ANDA applicant
Method-of-use patents	May affect labeling and carve-out strategies
Formulation patents	May block specific compositions or processes
Pediatric exclusivity	Adds six months only if awarded
Patent litigation	Can delay approval or launch under the Hatch-Waxman framework

Exact expiration dates should be taken from the current FDA Orange Book and linked patent records. The 2013 approval date alone does not establish the last date of market exclusivity.

What is the Orange Book status of Duavee?

Duavee is an NDA product subject to the Hatch-Waxman framework. An ANDA applicant must address each listed patent through a Paragraph I, II, III, or IV certification, or through a section viii statement for a method-of-use patent.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder or patent owner files suit within 45 days, FDA approval of the ANDA can be subject to a statutory 30-month stay, subject to court rulings and regulatory exceptions.[3]

The commercial significance of Orange Book listings depends on whether they cover:

• The exact Duavee strength.
• The fixed combination.
• The tablet composition.
• A required method of use.
• A manufacturing feature that the ANDA must practice.
• Only a labeling indication that can be carved out.

Which companies are challenging Duavee patents?

No reliable conclusion on current Paragraph IV filers, patent litigation, or settlement agreements should be drawn without reviewing the latest FDA Paragraph IV database, district-court docket records, and Orange Book entries. The relevant competitor set would include generic manufacturers with estrogen/SERM development capabilities, not biosimilar companies.

What generic entry risks exist for Duavee?

The primary risk is an ANDA that uses the same active ingredients and strength but substitutes excipients and manufacturing steps. A generic applicant may avoid a formulation patent by selecting a different filler, lubricant, coating, or granulation process, provided that the product remains pharmaceutically equivalent and bioequivalent.

Key technical barriers include:

• Demonstrating uniformity of the low-dose conjugated-estrogen fraction.
• Establishing comparable dissolution for both active components.
• Controlling the quality of a chemically heterogeneous estrogen mixture.
• Matching or adequately characterizing bazedoxifene exposure.
• Managing stability under accelerated and long-term conditions.
• Developing validated methods for multiple estrogenic components.
• Producing a stable tablet at commercial scale.

A generic applicant may also pursue a label carve-out for osteoporosis prevention or vasomotor symptoms if patent claims are indication-specific. Whether a carve-out is commercially viable depends on the remaining unpatented indication and physician prescribing behavior.

Is there a biosimilar risk for Duavee?

There is no biosimilar pathway risk because Duavee is a chemically synthesized small-molecule combination tablet, not a biologic. The relevant competitive threats are:

• ANDA-based generic tablets.
• Authorized generic distribution.
• Compounded or non-equivalent hormone products.
• Alternative menopausal hormone therapies.
• Estrogen plus progestin regimens.
• Selective estrogen receptor modulator products.
• Nonhormonal vasomotor therapies.

The absence of biosimilar risk does not eliminate substitution pressure. Generic competition can be more direct because an ANDA applicant can seek pharmaceutical equivalence rather than biosimilarity.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue Duavee-related opportunities in four areas.

Co-processed direct-compression systems

A co-processed filler-binder could improve flow, compressibility, and low-dose blend uniformity. The strongest value proposition would be reduced tablet-weight variability and consistent dissolution across scale-up batches.

Low-moisture excipient platforms

Low-moisture cellulose, lactose, mannitol, or multifunctional excipient systems could support improved stability and less demanding packaging.

Film-coating systems

A ready-to-use coating system could reduce process development time and improve color, adhesion, moisture protection, and throughput. Colorant and titanium dioxide requirements may differ by jurisdiction, creating an opportunity for regional coating variants.

Excipient systems for lactose-free reformulation

Mannitol-cellulose and other co-processed systems could support a lactose-free Duavee equivalent. The commercial case would depend on patient preference, manufacturing cost, and whether the reformulation creates a meaningful labeling or market-access advantage.

How does Duavee compare with competing menopausal therapies?

Product or therapy	Active approach	Main competitive distinction
Duavee	Conjugated estrogens plus bazedoxifene	Vasomotor symptom treatment and osteoporosis prevention without a conventional progestin
Premarin	Conjugated estrogens	Estrogen-only therapy, generally for women without a uterus
Estrogen plus progestin products	Estrogen and progestin	Broad menopause use but different endometrial and tolerability profile
Osphena	Ospemifene	Oral SERM for dyspareunia associated with vulvar and vaginal atrophy
Veozah	Fezolinetant	Nonhormonal vasomotor symptom treatment
Local vaginal estrogen	Low-dose estrogen products	Primarily genitourinary symptom management

Duavee’s formulation value is tied to its fixed-dose combination and its positioning for women who need systemic estrogen but seek an alternative to conventional progestin protection. Its main commercial vulnerability is the availability of several therapeutic substitutes with different safety, cost, and prescribing profiles.

Are there licensing opportunities for Duavee excipients or formulations?

Potential licensing structures include:

• A co-processed excipient licensed to a generic manufacturer.
• A lactose-free composition licensed under a formulation patent.
• A moisture-barrier coating platform licensed for regional commercialization.
• A manufacturing process that reduces blend-uniformity failures.
• A bioequivalence-enabling formulation package.
• An authorized-generic supply agreement.
• A contract manufacturing arrangement with proprietary excipient know-how.

A licensable formulation must provide measurable value. Relevant endpoints include lower content-uniformity variability, fewer stability failures, lower tablet-weight variation, reduced compression force, faster dissolution development, or lower packaging cost.

A formulation patent should claim a defensible technical feature rather than merely list conventional excipients. Stronger claims may combine composition limits with measurable performance parameters, such as blend uniformity, dissolution, water activity, particle-size distribution, or stability thresholds.

What manufacturing and IP barriers matter most?

The principal manufacturing barrier is the low-dose, multi-component estrogen fraction. The principal IP barrier is the scope of claims covering the fixed combination, dose ratio, therapeutic use, and any required formulation limitation.

A practical freedom-to-operate review should examine:

1. Current Orange Book patents for NDA 022247.
2. Continuation and divisional patent families.
3. Terminal disclaimers and patent-term adjustments.
4. USPTO assignment records for Pfizer and related entities.
5. Paragraph IV certifications and litigation complaints.
6. Settlement agreements and launch dates.
7. European and other national patent families.
8. Claims covering manufacturing intermediates or analytical methods.
9. Regulatory exclusivity codes.
10. The proposed generic label and indication carve-outs.

Key Takeaways

• Duavee is a fixed-dose tablet containing conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg.
• Its disclosed excipients include lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate, polydextrose, polyethylene glycol, sucrose, titanium dioxide, and triacetin.
• The strongest excipient opportunities involve low-dose content uniformity, moisture control, lubricant optimization, coating performance, and lactose-free substitution.
• Duavee faces generic, not biosimilar, competition.
• A generic manufacturer can potentially design around formulation claims by changing diluents, lubricants, coatings, or manufacturing processes.
• The fixed-dose active combination and method-of-use claims may provide stronger protection than conventional excipient claims.
• The current Orange Book and patent docket determine the practical generic-entry date.
• Licensing value will depend on measurable improvements in manufacturability, stability, bioequivalence development, or cost.

FAQs

Can Duavee be reformulated with mannitol instead of lactose?

Yes, a mannitol-based formulation is technically plausible, but it would require comparative dissolution, stability, content-uniformity, and bioequivalence evaluation.

Could a generic Duavee use different film-coating colors?

Possibly. Color and coating composition may be changed if the product remains pharmaceutically equivalent, meets regulatory requirements, and does not infringe an applicable composition or trade-dress right.

Is a new excipient likely to create regulatory exclusivity for Duavee?

Use of a novel excipient does not automatically create exclusivity. Regulatory protection would depend on the approval pathway, the clinical evidence, and whether the formulation supports qualifying new clinical investigations.

Can an excipient patent block all Duavee generics?

Usually not. A narrowly drafted excipient patent may block only products that practice its claimed composition or process. Generic applicants may avoid infringement through formulation design-around.

What is the highest-value Duavee formulation improvement?

Improved uniformity and stability of the low-dose conjugated-estrogen component are likely to have the greatest development and commercial value because they address the core manufacturing risks of the combination tablet.

References

1. U.S. Food and Drug Administration. (2013). Duavee (conjugated estrogens/bazedoxifene acetate) prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).